Imugene
Manufacturing · Australia · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Suite 12.01 Level 12 Bligh House 4-6 Bli...Phone Number
(805) 795-1131Website
www.imugene.comRevenue
$71.9 MillionStock Symbol
IMUIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Imugene
Imugene, founded in 2012 and headquartered in Sydney, Australia, is a biotechnology company that develops a range of cancer immunotherapy treatments.Explore more
Imugene Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Imugene your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Imugene has new funding data
Earning: See what the market has to say on Imugene recently announced quarterly report
Click to see if Imugene had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Imugene
Website visits: Recent activity has been detected on your website
Check if Imugene has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Imugene launches new products
Imugene, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Imugene is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Imugene as Masked Content
Find 3 more new buyers
Compare Similar Companies to Imugene
Compare insights from companies similar to Imugene, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Imugene is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Imugene is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Imugene.
Imugene financials insights
Gather financial insights about Imugene, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Share Placement
$18.2M
Imugene Tech Stack
A closer look at the technologies used by Imugene
See more technologies
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Person-Based
Person-Based
Imugene News & Media
Imugene launches $20M capital raise to advance azer-cel clinical program
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has launched a capital raising of up to $20 million through a combination of an institutional placement and a share purchase plan (SPP), with funds earmarked to support the continued clinical development of its azer-cel cancer therapy. The...Imugene secures FDA support for Azer-cel registrational pathway - Biotech Dispatch
Imugene (ASX:IMU) has taken a significant step toward potential commercialisation of its allogeneic CAR-T therapy azercabtagene zapreleucel, after receiving supportive written minutes from the US Food and Drug Administration outlining a clear route to a Phase 3 registrational trial.Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors. The collaboration includes...Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors. The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers. This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic vir
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Imugene
Sign Up For FreeTo access detailed company insights
Imugene, founded in 2012 and headquartered in Sydney, Australia, is a biotechnology company that develops a range of cancer immunotherapy treatments.... Read More
